Seniprutug
Based on 1 Customer Validation
Seniprutug (BCD-180) is a humanized monoclonal antibody targeting the TRBV9 fragment. Seniprutug induces antibody-dependent cell-mediated cytotoxicity to eliminate TRBV9+ T cells. Seniprutug is applicable to research related to active radiographic axial spondyloarthritis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.36%
- CAS 番号: 2484772-72-5
- 分子量:146.42 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human IgG1 kappa
Human
TRBV9
Seniprutug selectively targets the TRBV9 segment of the T cell receptor β chain, depletes TRBV9+ T cells, while preserving the remaining T cell repertoire[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
28586 [NCBI]
A0A0B4J1U6
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
化学情報
-
CAS 番号 2484772-72-5
-
性状 Liquid
-
分子量 146.42 kDa
-
Color Colorless to light yellow
-
別名
BCD-180
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Nasonov EL, et al. The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA. Dokl Biochem Biophys. 2025;522(1):387-403. [Content Brief]
[2]. Um J, et al. Mechanistic Insights from Human Studies in Axial Spondyloarthritis: A T Cell Story. Curr Rheumatol Rep. 2026;28(1):6. Published 2026 Mar 5. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Seniprutug 関連分類
HY-P990762 関連分類
Powered by Bioz